PFE
Latest Trade
53.76USDChange
-0.36(-0.66%)Volume
12,928,756Today's Range
-
54.4952 Week Range
-
61.71As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 54.11 |
|---|---|
Open | 53.65 |
Volume | 12,928,756 |
3M AVG Volume | 897.00 |
Today's High | 54.49 |
Today's Low | 53.49 |
52 Week High | 61.71 |
52 Week Low | 33.36 |
Shares Out (MIL) | 5,612.87 |
Market Cap (MIL) | 308,427.00 |
Forward P/E | 12.99 |
Dividend (Yield %) | 2.91 |
Pfizer files for Swiss authorization of COVID-19 drug
Canada Receives 30,400 Courses Of Pfizer's COVID-19 Oral Antiviral Treatment; 120,000 More Expected By End-March - Statement
U.S. FDA Approves Pfizer’s Cibinqo For Adults With Moderate-To-Severe Atopic Dermatitis
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The Company works across markets to develop wellness, prevention, treatments and cures. It collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. Its medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. In the United States, it sells its vaccines products to the federal government, centers for disease control and prevention (CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery networks.
Industry
Biotechnology & Drugs
Executive Leadership
Albert Bourla
Chairman of the Board, Chief Executive Officer
Angela Hwang
Group President, Pfizer Biopharmaceuticals Group
Payal Sahni
Chief Human Resource Officer, Executive Vice President
Lidia Fonseca
Executive Vice President, Chief Technology Officer and Digital Officer
Rady A. Johnson
Executive Vice President, Chief Compliance, Quality and Risk Officer
Price To Earnings (TTM) | 16.55 |
|---|---|
Price To Sales (TTM) | 4.45 |
Price To Book (MRQ) | 4.07 |
Price To Cash Flow (TTM) | 12.89 |
Total Debt To Equity (MRQ) | 52.69 |
LT Debt To Equity (MRQ) | 47.89 |
Return on Investment (TTM) | 13.46 |
Return on Equity (TTM) | 10.59 |
Canada on Monday approved Pfizer Inc's oral antiviral treatment for mild to moderate cases of COVID-19 in adults, but said global supply shortages meant only a few doses would be ready now.
* CANADA HAS RECEIVED SHIPMENT OF 30,400 TREATMENT COURSES OF PFIZER’S COVID-19 ORAL ANTIVIRAL TREATMENT; 120,000 MORE EXPECTED BY END OF MARCH - STATEMENT Source text : https://bit.ly/3FGHF2F
A fourth shot of COVID-19 vaccine boosts antibodies to even higher levels than the third jab but it is not enough to prevent Omicron infections, according to a preliminary study in Israel.
President Emmanuel Macron on Monday touted 21 new foreign investment projects in France and a booming economy as proof his economic reforms have been bearing fruit less than three months before a presidential election in which he is expected to run.
* CANADA HAS APPROVED PFIZER'S COVID-19 ORAL ANTIVIRAL TREATMENT - GOVERNMENT WEBSITE Source text for Eikon: Further company coverage: (Reporting by David Ljunggren)
Canada has approved Pfizer Inc's COVID-19 oral antiviral treatment, the Canadian Broadcasting Corp said on Monday, citing sources, and said an announcement could be made later in the day.
Pfizer will add a production facility for its antiviral COVID-19 pill in France as part of a plan to invest 520 million euros ($594 million) in the country over the next five years, the U.S. drugmaker said on Monday.
* GSK AND PFIZER HOLD OUT FOR £60BN BID FOR CONSUMER HEALTH UNIT - FT
The U.S. Food and Drug Administration approved drugs from AbbVie Inc and Pfizer Inc for treating eczema, a skin disease, the companies said on Friday.
The U.S. Food and Drug Administration approved Pfizer Inc's drug Cibinqo to treat eczema, a skin disease, the company said on Friday.
Mexican health regulator COFEPRIS said on Friday it had approved U.S. pharmaceutical company Pfizer's antiviral oral treatment against COVID-19 for emergency use in adults with light or moderate risk of complications.
The World Health Organization (WHO) is currently reviewing Merck's COVID-19 antiviral oral pill molnupiravir and a recommendation will likely be made by early February, an agency official said on Friday.
U.S. drugmaker Pfizer Inc said on Friday it has applied for Japanese government approval for its oral COVID-19 treatment.
Pfizer Inc said on Friday it applied for Japanese government approval for its oral COVID-19 treatment.
Recent comments from Pfizer Chief Executive Officer Albert Bourla on how two doses of the Pfizer-BioNTech COVID-19 vaccine offer “very limited protection” against the Omicron variant of the coronavirus have been misrepresented online.
Africa's top public health body said it was in talks with Pfizer about securing supplies of its antiviral COVID-19 pills for the continent, the latest to join the race for a drug seen as a potential game changer in fighting the virus.
Africa's top public health body is in talks with Pfizer about bringing its treatment pill for COVID-19 to the continent, its director said on Thursday.
South Korea will begin treating coronavirus patients with Pfizer's antiviral pills on Friday, the first Asian country to do so, as concern mounts over the spread of the highly contagious Omicron variant.
South Korea will begin treating coronavirus patients with Pfizer's antiviral pills on Friday, health officials said, as concern mounts over the spread of the highly contagious Omicron variant.
Pfizer Inc said on Wednesday booster doses of its COVID-19 vaccine can be administered along with its pneumonia vaccine and produced strong safety and immune responses in people aged 65 and above in a late-stage study.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.